ANGO Novinky na Forexe
AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update
While reporting financial results for the first quarter on Thursday, medical technology company AngioDynamics, Inc. (ANGO) reiterated its adjusted loss and net sales guidance for the full year 2027, based on its first quarter performance and current outlook for the remainder of the fiscal year.
RTTNews
|
Pred 45 dňami
AngioDynamics Q3 Loss Sharply Widens; Slashes FY24 Outlook
While reporting financial results for the third quarter on Thursday, medical devices company AngioDynamics, Inc. (ANGO) slashed its adjusted loss and net sales guidance for the full year 2024, reflecting the recent divestiture of the PICC and Midline businesses and discontinuance of the RadioFrequency ablation and Syntrax businesses.
RTTNews
|
Pred 962 dňami
AngioDynamics Q2 Results Miss Estimates; Boosts FY24 Adj. EPS Outlook
While reporting financial results for the second quarter on Thursday, medical devices company AngioDynamics, Inc. (ANGO) raised its adjusted earnings guidance for the full year 2024, while trimming annual net sales outlook.
RTTNews
|
Pred 1052 dňami
AngioDynamics Q1 Results Miss Estimates; Reaffirms FY23 Outlook
While reporting financial results for the first quarter on Thursday, medical devices company AngioDynamics, Inc. (ANGO) reaffirmed its adjusted earnings and net sales guidance for the full year 2023.
RTTNews
|
Pred 1508 dňami



